Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A young male presents with severe asthma. The pharmacokinetics of theophylline include the following parameters: Vd = 35 L; CL = 48 mL/min; half-life = 8 hours. If an intravenous infusion of theophylline is started at a rate of 0.48 mg/min, how long will it take to reach 93.75% of the steady state concentration?

Approximately 32 hours. **Explanation:** The core concept tested here is the **relationship between half-life ($t_{1/2}$) and the time required to reach steady-state concentration ($C_{ss}$)** during a continuous drug infusion. 1. **Why Option D is Correct:** In pharmacokinetics, the approach to steady state is a first-order process. It is a high-yield rule that the time taken to reach steady state depends **only on the half-life** of the drug, not on the dose or infusion rate. * After 1 $t_{1/2}$: 50% of $C_{ss}$ is reached. * After 2 $t_{1/2}$: 75% of $C_{ss}$ is reached. * After 3 $t_{1/2}$: 87.5% of $C_{ss}$ is reached. * **After 4 $t_{1/2}$: 93.75% of $C_{ss}$ is reached.** * After 5 $t_{1/2}$: 96.8% (~97%) of $C_{ss}$ is reached. Given the half-life ($t_{1/2}$) is **8 hours**, the time to reach 93.75% is $4 \times 8 \text{ hours} = \mathbf{32 \text{ hours}}$. 2. **Why Other Options are Incorrect:** * **Option A (48 mins):** This is a distractor using the Clearance (CL) value. * **Option B (5.8 hours):** This is a distractor using the $V_d$ or incorrect math. * **Option C (8 hours):** This represents only 1 half-life (50% of $C_{ss}$), which is insufficient. 3. **Clinical Pearls for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives** to reach clinical steady state. * **Loading Dose:** If a rapid effect is needed (like in acute asthma), a **loading dose** ($LD = V_d \times \text{Target } C_p$) is given to bypass the delay in reaching steady state. * **Elimination:** Similarly, it takes 4–5 half-lives for a drug to be completely eliminated from the body after stopping the infusion. * **Theophylline:** It has a narrow therapeutic index; toxicity can occur if clearance is decreased (e.g., by Cimetidine or Erythromycin).

Q: First-pass metabolism is a significant problem for drugs administered via which route?

Oral route (directly into stomach). **Explanation:** **1. Why the Oral Route is Correct:** The **Oral route** is the most common route associated with significant **First-pass metabolism** (Presystemic metabolism). When a drug is swallowed, it is absorbed from the gastrointestinal tract into the **portal venous system**. Before reaching the systemic circulation, the drug must pass through the **liver**, which is the primary site for drug metabolism. If the liver has a high extraction ratio for a specific drug, a large fraction of the dose is inactivated before it can reach its target site, significantly reducing its **bioavailability**. **2. Analysis of Incorrect Options:** * **Sublingual route:** Drugs absorbed through the buccal mucosa drain directly into the superior vena cava, bypassing the portal circulation and the liver. This is why Nitroglycerin is given sublingually for rapid action. * **Rectal route:** The rectal venous drainage is divided. The lower part bypasses the liver, while the upper part enters the portal system. Thus, it only partially avoids first-pass metabolism (roughly 50%). * **Intramuscular route:** This is a parenteral route where the drug is absorbed directly into the systemic capillaries, completely bypassing the gastrointestinal tract and the first pass through the liver. **3. NEET-PG High-Yield Pearls:** * **Bioavailability (F):** For intravenous (IV) administration, F = 100%. For oral drugs with high first-pass metabolism (e.g., Propranolol, Lidocaine, Morphine, Nitroglycerin), F is significantly low. * **Lidocaine:** It has such high first-pass metabolism that it is practically ineffective when given orally; hence, it is used parenterally as an anti-arrhythmic. * **Propranolol:** Shows significant individual variation in oral bioavailability due to first-pass effects, requiring much higher oral doses compared to IV doses.

Q: All the following drugs act by intracellular receptors except?

Insulin. ### Explanation The correct answer is **Insulin**. **Mechanism of Action:** Receptors are broadly classified into two types based on the chemical nature of the ligand: **Cell Surface Receptors** (for water-soluble ligands) and **Intracellular Receptors** (for lipid-soluble ligands). * **Insulin** is a peptide hormone. Because it is large and hydrophilic, it cannot cross the lipid bilayer of the cell membrane. It acts via a **Cell Surface Receptor**, specifically a **Receptor Tyrosine Kinase (RTK)** [1]. Binding triggers autophosphorylation of the receptor, leading to downstream signaling (MAP kinase and PI3K pathways) [1]. **Analysis of Incorrect Options:** * **Thyroid Hormones (T3, T4):** These are unique because, despite being amino acid derivatives, they are lipophilic. They act on **Intranuclear receptors** to alter gene transcription. * **Vitamin D:** As a fat-soluble vitamin, it functions similarly to steroid hormones. It binds to the **Vitamin D Receptor (VDR)** located in the nucleus. * **Steroids:** Glucocorticoids, mineralocorticoids, and sex hormones are lipophilic. They cross the cell membrane to bind to **Cytoplasmic or Nuclear receptors**, forming a complex that acts as a transcription factor. **NEET-PG High-Yield Pearls:** 1. **Mnemonic for Intracellular Receptors:** **"VET TV"** (Vitamin D, Estrogen, Testosterone, Thyroid hormone, Vitamin A/Retinoic acid). 2. **Cytoplasmic vs. Nuclear:** While most steroids bind in the cytoplasm and then translocate, **Thyroid hormones and Estrogen** receptors are primarily located directly inside the **nucleus**. 3. **Speed of Action:** Hormones acting on intracellular receptors have a **slow onset** (hours to days) because they require protein synthesis, whereas surface receptors (like Insulin or Epinephrine) produce **rapid** effects.

Q: All of the following drugs are metabolized by acetylation, except?

Ketoconazole. **Explanation:** The question tests your knowledge of **Phase II metabolic reactions**, specifically **Acetylation**. This pathway is catalyzed by the enzyme *N-acetyltransferase* (NAT) in the liver. **Why Ketoconazole is the correct answer:** Ketoconazole is an imidazole antifungal that is primarily metabolized in the liver via **Oxidation** (Phase I reaction) through the **CYP3A4** enzyme system. It does not undergo acetylation. Notably, Ketoconazole is a potent inhibitor of CYP3A4, leading to numerous drug-drug interactions. **Analysis of Incorrect Options (Drugs that undergo Acetylation):** A classic mnemonic to remember drugs metabolized by acetylation is **"SHIP"**: * **S – Sulfonamides:** Used in various bacterial infections; their acetylated metabolites can sometimes cause crystalluria. * **H – Hydralazine:** An antihypertensive used in pregnancy-induced hypertension and heart failure. * **I – Isoniazid (INH):** A primary anti-tubercular drug. * **P – Procainamide:** A Class 1A antiarrhythmic. **High-Yield Clinical Pearls for NEET-PG:** 1. **Genetic Polymorphism:** Acetylation shows bimodal distribution in the population. Individuals are classified as **Fast Acetylators** or **Slow Acetylators**. 2. **Slow Acetylators:** These individuals are at a higher risk of drug-induced toxicity. Specifically, they are prone to **Drug-Induced Lupus Erythematosus (DILE)** when taking Hydralazine, Procainamide, or Isoniazid. 3. **Isoniazid Toxicity:** In slow acetylators, INH can cause peripheral neuropathy (due to Vitamin B6 deficiency), whereas fast acetylators may be more prone to INH-induced hepatotoxicity due to rapid conversion to acetylhydrazine.

Q: Which receptors on the cell membrane activate an ion channel after binding with agonists?

Nicotinic cholinergic. **Explanation:** The question tests the classification of cell surface receptors based on their signaling mechanisms. Receptors are broadly divided into **Ionotropic** (ligand-gated ion channels) and **Metabotropic** (G-protein coupled receptors). **1. Why Nicotinic Cholinergic is Correct:** Nicotinic receptors (both $N_m$ and $N_n$ subtypes) are classic examples of **ionotropic receptors**. Upon binding with an agonist (Acetylcholine), the receptor undergoes a conformational change that directly opens an integral ion channel. This allows the rapid influx of $Na^+$ (and efflux of $K^+$), leading to immediate membrane depolarization. This rapid action is essential for neuromuscular transmission and autonomic ganglionic signaling. **2. Why the other options are Incorrect:** * **Muscarinic Cholinergic (B):** These are **G-protein coupled receptors (GPCRs)**. They act through second messengers like $IP_3/DAG$ ($M_1, M_3$) or by inhibiting Adenylyl Cyclase ($M_2$). They do not contain an intrinsic ion channel. * **Opioid Mu Receptors (C):** These are **$G_i/G_o$ protein-coupled receptors**. They work by inhibiting adenylyl cyclase and indirectly modulating potassium and calcium channels via G-protein subunits, rather than being the channel themselves. * **GABA B Receptors (D):** Unlike GABA A (which is ionotropic/chloride channel), **GABA B is metabotropic (GPCR)**. It acts via G-proteins to increase $K^+$ conductance or decrease $Ca^{2+}$ influx. **High-Yield Clinical Pearls for NEET-PG:** * **Ionotropic Receptors (Fast):** Nicotinic (ACh), GABA A, Glycine, 5-HT3, and Glutamate (NMDA/AMPA) receptors. * **Metabotropic Receptors (Slow):** All Muscarinic, all Adrenergic, GABA B, and most Serotonin receptors (except 5-HT3). * **Exam Tip:** If a receptor's action results in "milli-second" speed responses, it is almost always an ionotropic receptor.

Q: Which of the following statements is true about steady state?

Rate of administration is equal to rate of elimination.. ### Explanation **1. Why Option A is Correct:** Steady state (Css) is a pharmacokinetic condition where the **rate of drug administration (input) equals the rate of drug elimination (output)**. At this point, the total amount of drug in the body remains constant, and the plasma concentration fluctuates within a stable range. Mathematically, it is represented as: *Rate of Infusion ($R_0$) = Clearance ($CL$) × Steady State Concentration ($C_{ss}$)*. **2. Analysis of Incorrect Options:** * **Option B:** This is incorrect because the time taken to reach steady state depends **solely on the half-life ($t_{1/2}$)** of the drug. It is independent of the dose or frequency of administration. * **Option C:** This is incorrect because the **magnitude** (level) of the plasma concentration at steady state is directly proportional to the dose rate. While the *time* to reach it is constant, a higher dose results in a higher steady-state concentration. * **Option D:** This is incorrect. A longer dosing interval allows more time for the drug to be eliminated between doses, leading to a **greater** fluctuation (wider gap) between peak ($C_{max}$) and trough ($C_{min}$) levels. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rule of 4-5:** It takes approximately **4 to 5 half-lives** to reach steady state (94% at 4 $t_{1/2}$; 97% at 5 $t_{1/2}$). * **Loading Dose:** If clinical urgency requires reaching steady state immediately, a **Loading Dose** is given. However, even with a loading dose, the "true" steady state of the body is only maintained after 4-5 half-lives. * **Elimination:** Similarly, it takes 4-5 half-lives for a drug to be completely eliminated from the body after stopping the infusion.

Q: Which is the most common phase-2 reaction in drug metabolism?

Glucuronide conjugation. Drug metabolism (biotransformation) typically occurs in two phases. Phase-1 (Non-synthetic) involves oxidation, reduction, and hydrolysis, while Phase-2 (Synthetic) involves conjugation reactions to make the drug more water-soluble for excretion [4]. **1. Why Glucuronide Conjugation is Correct:** Glucuronidation is the **most common and most important** Phase-2 reaction [2]. It is mediated by the enzyme **UDP-glucuronosyltransferase (UGT)**. Its dominance is due to the high availability of the substrate (glucuronic acid, derived from glucose) and the wide variety of functional groups (hydroxyl, carboxyl, amino) it can bind to [3]. Most drugs, including morphine, paracetamol, and lorazepam, undergo this process. **2. Analysis of Incorrect Options:** * **Acetylation (B):** Common for drugs like Isoniazid, Hydralazine, and Procainamide (remembered by the mnemonic **SHIP**). It is clinically significant due to genetic polymorphism (fast vs. slow acetylators) but is not the most frequent reaction. * **Methylation (C):** A relatively minor pathway involving enzymes like COMT (for catecholamines) or TPMT (for thiopurines). * **Sulfate Conjugation (D):** Important for steroids and phenolic compounds, but the body has a limited pool of sulfate, making it less common than glucuronidation [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Exception to the Rule:** Most Phase-2 reactions result in inactivation, but **Morphine-6-glucuronide** is a potent active metabolite. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase-2 reaction carried out by microsomal enzymes; all other Phase-2 reactions are non-microsomal (cytosolic). * **Neonatal Physiology:** Newborns are deficient in glucuronyltransferase, leading to "Gray Baby Syndrome" when given Chloramphenicol.

Q: Atrial Natriuretic Peptide receptors belong to which of the following types of receptors?

Ligand-gated guanylyl cyclase receptor. **Explanation:** **Atrial Natriuretic Peptide (ANP)** and Brain Natriuretic Peptide (BNP) exert their physiological effects by binding to **Natriuretic Peptide Receptor-A (NPR-A)**. This receptor is a classic example of a **transmembrane (membrane-bound) Guanylyl Cyclase**. When ANP binds to the extracellular domain, it directly activates the intracellular catalytic domain of the receptor, which converts GTP into **cyclic GMP (cGMP)**. cGMP then activates Protein Kinase G (PKG), leading to vasodilation and natriuresis. This is distinct from soluble guanylyl cyclase, which is activated by Nitric Oxide. **Analysis of Incorrect Options:** * **A. G-protein coupled receptors (GPCRs):** These utilize secondary messengers like cAMP or $IP_3/DAG$. While many hormones use GPCRs, ANP does not. * **C. Tyrosine kinase receptors:** These (e.g., Insulin, EGF) involve autophosphorylation of tyrosine residues. ANP receptors lack tyrosine kinase activity. * **D. JAK-STAT receptors:** These are used by cytokines and Growth Hormone. They do not have intrinsic enzymatic activity but recruit cytosolic Janus Kinases (JAKs). **High-Yield Clinical Pearls for NEET-PG:** 1. **Dual Role:** ANP receptors are both the receptor and the enzyme (Guanylyl Cyclase). 2. **Sacubitril:** A Neprilysin inhibitor used in Heart Failure (ARNI) that prevents the degradation of ANP/BNP, thereby increasing cGMP levels. 3. **Nesiritide:** A recombinant form of BNP used in acute decompensated heart failure, acting via this same cGMP pathway. 4. **Other cGMP-linked drugs:** Sildenafil (PDE-5 inhibitor) prevents the breakdown of the cGMP generated by these pathways.

Q: Which of the following statements regarding drug action is true?

Clinical efficacy is more important than potency.. ### Explanation **1. Why Option A is Correct:** In clinical practice, **efficacy** is the most important parameter of drug action. Efficacy (or maximal efficacy) refers to the maximum therapeutic effect a drug can produce, regardless of the dose. For example, if Patient X has severe pain, a drug with high efficacy (like Morphine) will provide relief, whereas a drug with low efficacy (like Aspirin) may never reach that level of pain control, no matter how much the dose is increased. **Potency**, on the other hand, refers to the amount of drug (dose) required to produce a specific intensity of effect. A "more potent" drug simply requires a smaller dose (e.g., 5mg vs. 500mg) to achieve the same result. Since we can easily adjust the dose or tablet size, potency is rarely a limiting factor in treatment, making efficacy the clinically superior metric. **2. Why Other Options are Incorrect:** * **Option B:** Potency is primarily of academic interest and helps in determining the dose for a prescription. It does not dictate the ultimate therapeutic success. A highly potent drug that lacks efficacy is useless for severe pathology. * **Option C:** While both are pharmacological properties, they are not "equally" important in a clinical setting. Efficacy determines the "ceiling effect" of treatment, which is the primary concern for a physician. **3. NEET-PG High-Yield Pearls:** * **Dose-Response Curve (DRC):** On a graph, **Potency** is represented by the position of the curve along the **X-axis** (left = more potent), while **Efficacy** is represented by the height on the **Y-axis**. * **Clinical Rule:** A drug that is more efficacious is often preferred over one that is merely more potent. * **ED50:** The dose that produces a response in 50% of individuals is used to measure potency.

Question 1

A young male presents with severe asthma. The pharmacokinetics of theophylline include the following parameters: Vd = 35 L; CL = 48 mL/min; half-life = 8 hours. If an intravenous infusion of theophylline is started at a rate of 0.48 mg/min, how long will it take to reach 93.75% of the steady state concentration?

Accepted Answer

Approximately 32 hours

Answer

Approximately 48 minutes

Answer

Approximately 5.8 hours

Answer

Approximately 8 hours

Question 2

First-pass metabolism is a significant problem for drugs administered via which route?

Accepted Answer

Oral route (directly into stomach)

Answer

Sublingual route

Answer

Rectal route

Answer

Intramuscular route

Question 3

All the following drugs act by intracellular receptors except?

Accepted Answer

Insulin

Answer

Thyroid hormones

Answer

Vitamin D

Answer

Steroids

Question 4

All of the following drugs are metabolized by acetylation, except?

Accepted Answer

Ketoconazole

Answer

Isoniazid (INH)

Answer

Sulfonamides

Answer

Hydralazine

Question 5

Which receptors on the cell membrane activate an ion channel after binding with agonists?

Accepted Answer

Nicotinic cholinergic

Answer

Muscarinic cholinergic

Answer

Opioid mu receptors

Answer

GABA B receptors

Question 6

Which of the following statements is true about steady state?

Accepted Answer

Rate of administration is equal to rate of elimination.

Answer

It does not depend upon half-life.

Answer

Plasma concentration achieved is independent of dose rate.

Answer

The longer the dosing interval, the lesser the difference between peak and trough values.

Question 7

Which is the most common phase-2 reaction in drug metabolism?

Accepted Answer

Glucuronide conjugation

Answer

Acetylation

Answer

Methylation

Answer

Sulfate conjugation

Question 8

Atrial Natriuretic Peptide receptors belong to which of the following types of receptors?

Accepted Answer

Ligand-gated guanylyl cyclase receptor

Answer

G-protein coupled receptors

Answer

Tyrosine kinase receptors

Answer

JAK-STAT receptors

Question 9

Which of the following statements regarding drug action is true?

Accepted Answer

Clinical efficacy is more important than potency.

Answer

Clinical potency is more important than efficacy.

Answer

Both potency and efficacy are equally important clinically.

Answer

None of the above statements are true.

Question 10

Low V4 means:

Accepted Answer

The drug does not accumulate in tissues.

Answer

The drug has a low half-life.

Answer

The drug has low bioavailability.

Answer

The drug has weak plasma protein binding.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?